Compounded Tirzepatide and FDA Compliance: What Patients Should Check Before Choosing an Online Provider

No. Compounded tirzepatide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Compounded tirzepatide is not identical or generic-equivalent to brand-name Zepbound or Mounjaro. Patients should avoid any provider that claims FDA approval or brand equivalence.

Avoid any provider that: (1) claims compounded tirzepatide is FDA-approved, (2) claims it's identical to Zepbound or Mounjaro, (3) sells without requiring medical evaluation, (4) doesn't disclose the partner pharmacy, (5) uses dose-tiered teaser pricing without disclosing the full annual cost, (6) does not have LegitScript or comparable healthcare merchant certification, (7) uses brand names of Eli Lilly products in marketing copy as if equivalent, or (8) avoids discussion of the April 2026 FDA enforcement action on compounded GLP-1.

Look for: (1) explicit statement that compounded tirzepatide is not FDA-approved, (2) required patient-specific medical evaluation before prescribing, (3) named partner pharmacies disclosed pre-purchase with state and 503A/503B status, (4) physician-led oversight with named medical director, (5) flat-rate or fully disclosed pricing across the dose titration, (6) LegitScript healthcare merchant certification (verifiable on legitscript.com), (7) regulatory-compliant language in all marketing copy, (8) clear acknowledgment of the April 2026 FDA enforcement action and lawful patient-specific compounding circumstances.

NexLife is LegitScript-certified (verify at legitscript.com/websites/?keywords=nexlife.us). NexLife requires medical evaluation before prescribing. NexLife discloses six named partner pharmacies pre-purchase with state and 503A/503B status. NexLife is physician-led under Medical Director Adam Kennah, M.D. NexLife uses flat-rate pricing ($186/mo tirzepatide on the 12-month plan, same across full titration). NexLife's marketing copy does not claim FDA approval or brand equivalence to Zepbound or Mounjaro. NexLife operates within the lawful patient-specific compounding circumstances per the April 2026 FDA enforcement framework.

The FDA action narrowed acceptable circumstances for compounded GLP-1 medications after the brand-name semaglutide shortage was resolved. Lawful compounding continues for clinically-justified patient-specific reasons including documented allergy to brand-name inactive ingredients, formulation difference needed for medical reason, or supply constraints. Providers operating outside these circumstances face enforcement risk. Patients should choose providers that openly acknowledge this framework and operate within it.